IMVARIA Showcases Real-World Success of FDA-Authorized AI Tool Fibresolve for Lung Disease Diagnosis at ATS 2025
IMVARIA Inc., a trailblazing health tech company specializing in AI-driven digital biomarker solutions, is making waves in the medical community with its groundbreaking diagnostic service, Fibresolve. The company recently shared insights from multi-site clinical experiences where pulmonologists utilized Fibresolve to evaluate suspected cases of Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF). As the first-ever FDA-authorized AI-powered adjunctive diagnostic tool for lung fibrosis, Fibresolve is transforming how clinicians approach these complex respiratory conditions.
The findings will be presented by pulmonary experts from Harvard’s Massachusetts General Hospital at the ATS 2025 International Conference, held from May 16-21, 2025, in San Francisco. This prestigious event focuses on advancements in respiratory diseases, making it the ideal platform to highlight the real-world impact of IMVARIA’s innovative technology.
Revolutionizing Pulmonary Diagnostics with AI
Fibresolve represents a significant leap forward in diagnosing ILD and IPF, two conditions that pose challenges due to their complexity and the need for accurate, timely assessments. Built by medical doctors with deep software engineering expertise, Fibresolve was designed to seamlessly integrate into existing clinical workflows, ensuring minimal disruption while delivering actionable insights.
“We’re thrilled that our clinical users are sharing their real-world experiences with Fibresolve at the ATS Conference,” said Dr. Joshua Reicher, Co-founder and CEO of IMVARIA. “Our approach to AI is unique—it prioritizes usability and reliability, empowering pulmonologists to adopt cutting-edge technology without overhauling their routines or installing cumbersome systems.”
Dr. Reicher, along with co-founder Dr. Michael Muelly, emphasized that Fibresolve adheres to the highest medical standards. By combining advanced AI algorithms with a user-friendly interface, the tool provides clinicians with new diagnostic insights while maintaining ease of use. This focus on practicality has earned widespread praise from healthcare professionals who have integrated Fibresolve into their practices.
FDA Authorization and Clinical Validation
Fibresolve received FDA authorization in early 2024 after undergoing a rigorous evaluation process to ensure its safety, efficacy, and reliability. The service operates through IMVARIA’s centralized platform, which leverages AI to guide non-invasive diagnoses, reducing the need for invasive procedures like biopsies. This not only enhances patient comfort but also streamlines the diagnostic process for clinicians.
What sets Fibresolve apart is its distinction as the first FDA Breakthrough-Designated AI diagnostic tool with simultaneously adopted CPT billing codes approved by the American Medical Association (AMA). This achievement underscores the tool’s innovation and its potential to revolutionize pulmonary care.
Real-World Impact Across Multiple Sites
Clinical data collected from various sites across the U.S. highlights Fibresolve’s effectiveness in aiding pulmonologists. By analyzing high-resolution CT scans, the AI-powered tool identifies patterns indicative of ILD and IPF, providing clinicians with critical information to support diagnosis and treatment planning. Early adopters report improved diagnostic accuracy, faster decision-making, and enhanced confidence in managing challenging cases.
One key advantage of Fibresolve is its ability to reduce diagnostic uncertainty, particularly in early-stage ILD and IPF cases where subtle imaging features may be overlooked. By flagging abnormalities and offering detailed analyses, the tool acts as a valuable second opinion, ensuring patients receive appropriate care sooner.
Expanding IMVARIA’s Pulmonary Portfolio
In addition to showcasing Fibresolve, IMVARIA is presenting data on two other innovative AI solutions in its pulmonary portfolio: ScreenDx and Bronchosolve.
- ScreenDx: FDA-cleared in 2025, ScreenDx is the first AI technology authorized to assess interstitial lung findings compatible with ILD. It serves as an early detection tool, helping clinicians identify potential issues before they progress.
- Bronchosolve: Still under research investigation, Bronchosolve aims to improve the assessment of indeterminate lung nodules. By leveraging AI, this investigational tool seeks to enhance diagnostic precision and reduce unnecessary interventions.
Together, these solutions demonstrate IMVARIA’s commitment to advancing pulmonary medicine through AI-driven innovations.
Why AI is Transforming Respiratory Care
The growing prevalence of respiratory diseases underscores the urgent need for better diagnostic tools. According to recent studies, ILD affects millions worldwide, with IPF being one of the most severe forms. Early and accurate diagnosis is crucial for improving outcomes, yet traditional methods often fall short due to variability in interpretation and limited access to specialists.
AI-powered tools like Fibresolve address these gaps by standardizing analysis and providing consistent, objective results. For pulmonologists, this means greater confidence in their diagnoses and the ability to focus on personalized patient care. For patients, it translates to quicker answers, reduced anxiety, and more effective treatment plans.
A New Era in Pulmonary Medicine
As IMVARIA continues to refine its AI technologies, the company remains dedicated to addressing unmet needs in respiratory care. By collaborating with leading institutions and incorporating feedback from clinical users, IMVARIA ensures its solutions remain at the forefront of innovation.
The presentation at ATS 2025 marks a pivotal moment for IMVARIA and the broader medical community. With Fibresolve paving the way, AI is no longer just a futuristic concept—it’s a practical, reliable tool that’s already making a difference in real-world settings.
For healthcare providers seeking to enhance their diagnostic capabilities, IMVARIA’s suite of AI solutions offers a glimpse into the future of pulmonary care. By bridging the gap between cutting-edge technology and clinical practice, IMVARIA is redefining what’s possible in the fight against respiratory diseases.
About IMVARIA Inc.
IMVARIA is a health tech company pioneering AI-driven solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates its AI Lab with automated, machine-learning algorithm technology to transform clinical decision-making into data science. IMVARIA is based in Berkeley, CA. For more information, go to www.imvaria.com.
